Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis

Blood

Volumn 125, Issue 21, 2015, Pages 3347-3350

  Kröger, Nicolaus ^a   Giorgino, Toni ^b   Scott, Bart L ^c   Ditschkowski, Markus ^d   Alchalby, Haefaa ^a   Cervantes, Francisco ^e   Vannucchi, Alessandro ^f   Cazzola, Mario ^g   Morra, Enrica ^h   Zabelina, Tatjana ^a   Maffioli, Margherita ⁱ   Pereira, Arturo ^e   Beelen, Dietrich ^d   Deeg, H Joachim ^c   Passamonti, Francesco ⁱ  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CNR   (Italy)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY OF FLORENCE   (Italy)

^g UNIVERSITY OF PAVIA   (Italy)

^h OSPEDALE NIGUARDA CA GRANDA   (Italy)

ⁱ OSPEDALE DI CIRCOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; DYNAMIC INTERNATIONAL PROGNOSTIC SCORING SYSTEM; FEMALE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; INTERMEDIATE 1 RISK PATIENT; INTERMEDIATE 2 RISK PATIENT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; OUTCOME ASSESSMENT; PATIENT; PATIENT COUNSELING; PRIORITY JOURNAL; RISK; SPLEEN SIZE; SURVIVAL; ALLOGRAFT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; YOUNG ADULT;

ADULT; ALLOGRAFTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84930006828     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-10-608315     Document Type: Article

References (18)

1. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
2. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
3. Kröger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26):5264-5270.
4. Scott BL, Gooley TA, Sorror ML, et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood. 2012; 119(11):2657-2664.
5. Barbui T, Barosi G, Birgegard G, et al; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
6. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982;10(4):1100-1120.
7. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
8. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.
9. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2):579-585.
10. Brand R, Putter H, van Biezen A, et al. Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using nonrandomized data. PLoS ONE. 2013;8(10): e74368.
11. Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood. 2012;120(7):1367-1379.
12. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28(7):1494-1500.
13. Rumi E, Pietra D, Pascutto C, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7): 1062-1069.
14. Panagiota V, Thol F, Markus B, et al. Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Leukemia. 2014;28(7): 1552-1555.
15. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98(12): 1865-1871.
16. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-798.
17. Cervantes F, Vannucchi AM, Kiladjian JJ, et al; COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-4053.
18. Passamonti F, Maffioli M, Cervantes F, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood. 2014; 123(12):1833-1835.